ArticleMolecular biology reports2026
SPP1 integrates trophoblast-endothelial crosstalk via the αVβ3-PI3K/Akt-MMP-9 axis to govern vascular remodeling in preeclampsia.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPreeclampsia (PE) is a major hypertensive disorder of pregnancy rooted in defective placental vascular remodeling. Osteopontin (SPP1) is implicated in placental development, but its role in orchestrating the critical paracrine dialogue between trophoblasts and endothelial cells remains undefined.
methodsPlacental SPP1 expression and microvessel density (MVD) were analyzed in PE and control pregnancies. An in vitro hypoxia-reoxygenation (H/R) model with SPP1 manipulation in HTR-8/SVneo trophoblasts was used to assess cell functions. Trophoblast-endothelial communication was evaluated via a Transwell co-culture system with HUVECs. Key signaling (integrin αVβ3-PI3K/Akt/FAK) and the MMP-9/TIMP-1 balance were examined. Serum SPP1, sFlt-1, and PlGF were measured. In vivo, we established an N-nitro-L-arginine methyl ester (L-NAME)-induced PE rat model, and evaluated the therapeutic effect of recombinant SPP1 supplementation on PE-like phenotypes, placental vascular remodeling and the underlying signaling changes.
resultsSPP1 was downregulated in PE placentas and positively correlated with MVD. H/R reduced SPP1 secretion, impairing trophoblast invasion/proliferation and suppressing endothelial tube formation via paracrine signaling. Mechanistically, trophoblast-derived SPP1 promoted angiogenesis by activating endothelial integrin αVβ3-PI3K/Akt/FAK signaling and restoring the MMP-9/TIMP-1 balance. Downregulated SPP1 disrupts EVT-endothelial paracrine signaling required for spiral artery‑like remodeling. In vivo, SPP1 supplementation ameliorated PE phenotypes, restored placental vascular density, and reversed signaling defects in a rat model. Clinically, serum SPP1 levels were reduced in PE and inversely correlated with the sFlt-1/PlGF ratio and disease severity, highlighting its predictive value.
conclusionSPP1 is a central paracrine mediator of trophoblast-endothelial crosstalk, and its hypoxia-induced reduced expression drives vascular dysfunction in PE via the integrin αVβ3-PI3K/Akt-MMP-9/TIMP-1 axis. Our findings nominate SPP1 as both a promising biomarker and a potential therapeutic target for PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.